The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients
Conclusions.
SGLT2i improved a composite of all-cause mortality, DCGF, or serum creatinine doubling in KTRs. SGLT2i can be used safely and have beneficial effects on preserving graft function in diabetic KTRs.
Source: Transplantation - Category: Transplant Surgery Tags: Original Clinical Science—General Source Type: research
More News: Diabetes | Endocrinology | Kidney Transplant | Kidney Transplantation | Prograf | SGLT2 Inhibitors | Sodium | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology